{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T21:45:09Z","timestamp":1773697509332,"version":"3.50.1"},"reference-count":68,"publisher":"Informa UK Limited","issue":"1","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Metabolism & Toxicology"],"published-print":{"date-parts":[[2015,1,2]]},"DOI":"10.1517\/17425255.2015.986457","type":"journal-article","created":{"date-parts":[[2014,11,24]],"date-time":"2014-11-24T06:01:31Z","timestamp":1416808891000},"page":"125-137","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":9,"title":["Pharmacokinetics, pharmacodynamics and clinical efficacy of dapagliflozin for the treatment of type 2 diabetes"],"prefix":"10.1517","volume":"11","author":[{"given":"Marianna","family":"Maranghi","sequence":"first","affiliation":[{"name":"University of Rome \"Sapienza\", Department of Internal Medicine and Clinical Specialities","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Carnovale","sequence":"additional","affiliation":[{"name":"University of Rome \"Sapienza\", Department of Internal Medicine and Clinical Specialities","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cosimo","family":"Durante","sequence":"additional","affiliation":[{"name":"University of Rome \"Sapienza\", Department of Internal Medicine and Clinical Specialities","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanna","family":"Tarquini","sequence":"additional","affiliation":[{"name":"University of Rome \"Sapienza\", Department of Internal Medicine and Clinical Specialities","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giusy","family":"Tiseo","sequence":"additional","affiliation":[{"name":"University of Rome \"Sapienza\", Department of Internal Medicine and Clinical Specialities","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastiano","family":"Filetti","sequence":"additional","affiliation":[{"name":"University of Rome \"Sapienza\", Department of Internal Medicine and Clinical Specialities","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2014,11,24]]},"reference":[{"key":"e_1_3_2_3_1","unstructured":"Epidemiology and prevention of diabetes. IDF (International Diabetes Federation) Diabetes Atlas sixth edition. Available from: www.idf.org\/diabetesatlas\/introduction [Last accessed 6 September 2014]"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2013.02.010"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00045.2011"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amepre.2013.04.017"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S61438"},{"key":"e_1_3_2_8_1","volume-title":"National diabetes fact sheet: National estimates and general information on diabetes and prediabetes in the United States","author":"Centers for Disease Control and Prevention","year":"2011","unstructured":"Centers for Disease Control and Prevention. National diabetes fact sheet: National estimates and general information on diabetes and prediabetes in the United States. US Department of Health and Human Services, Centers for Disease Control and Prevention; Atlanta: 2011"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62154-6"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1210\/edrv.23.2.0461"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.2337\/diab.37.6.667"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.86.8.7750"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1210\/er.2006-0026"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2014.06.018"},{"issue":"5","key":"e_1_3_2_15_1","first-page":"s2","article-title":"Managing type 2 diabetes: going beyond glycemic control","volume":"14","author":"Stolar MW","year":"2008","unstructured":"Stolar MW, Hoogwerf BJ, Gorshow SM, et al. Managing type 2 diabetes: going beyond glycemic control. J Manag Care Pharm 2008;14(5 Suppl B):s2-19","journal-title":"J Manag Care Pharm"},{"key":"e_1_3_2_16_1","unstructured":"FDA guidance for industry diabetes mellitus - evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. 2008. Available from: http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm071627.pdf [Last accessed 6 September 2014]"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-S014"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-012-2534-0"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00055.2009"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1079\/BJN2002763"},{"key":"e_1_3_2_21_1","first-page":"453","article-title":"SGLT-2 inhibitors and their potential in the treatment of diabetes","volume":"27","author":"Rosenwasser RF","year":"2013","unstructured":"Rosenwasser RF, Sultan S, Sutton D, et al. SGLT-2 inhibitors and their potential in the treatment of diabetes. Diabetes Metab Syndr Obes 2013;27:453-67","journal-title":"Diabetes Metab Syndr Obes"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00232-001-0036-y"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.2003.046268"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2008.11.003"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI70704"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI72227"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI112981"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI113157"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.48.9.1794"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S22503"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12214"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S50773"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-013-0104-3"},{"key":"e_1_3_2_34_1","unstructured":"EMDAC Background Document Dapagliflozin BMS-512148 NDA 202293. 2013. Available from: www.fda.gov\/downloads\/advisorycommittees\/committeesmeetingmaterials\/drugs\/endocrinologicandmetabolicdrugsadvisorycommittee\/ucm378079.pdf [Last accessed 6 September 2014]"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2013.20"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-013-0128-8"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-011-0098-x"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01434.x"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-1801"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12056"},{"key":"e_1_3_2_41_1","unstructured":"US Full Prescribing Information and Medication Guide for Farxiga\u2122 (dapagliflozin) tablets. Available from: http:\/\/packageinserts.bms.com\/pi\/pi_farxiga.pdf [Last accessed 6 September 2014]"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2011.09.011"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2008.251"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S34416"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2012.01659.x"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-0612"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2012.02911.x"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-1863"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60407-2"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-11-43"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-2260"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12189"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-0467"},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01434.x"},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-1693"},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-0517"},{"key":"e_1_3_2_57_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-156-6-201203200-00003"},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-0606"},{"key":"e_1_3_2_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12327"},{"key":"e_1_3_2_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2010.01216.x"},{"key":"e_1_3_2_61_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.12881"},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2013.356"},{"key":"e_1_3_2_63_1","unstructured":"FDA Briefing Document NDA 202293. 2011. Available from: http:\/\/www.fda.gov\/downloads\/AdvisoryCommittee\/UCM262994.pdf [Last accessed 6 September 2014]"},{"key":"e_1_3_2_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2013.04.012"},{"key":"e_1_3_2_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2013.05.004"},{"key":"e_1_3_2_66_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12341"},{"key":"e_1_3_2_67_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12263"},{"key":"e_1_3_2_68_1","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S22545"},{"key":"e_1_3_2_69_1","unstructured":"Multicenter trial to evaluate the effect of dapagliflozin on the incidence of cardiovascular events (DECLARE-TIMI58) study design. Available from: http:\/\/clinicaltrials.gov\/show\/NCT01730534 [Last accessed 5 September 2014]"},{"key":"e_1_3_2_70_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S59169"}],"container-title":["Expert Opinion on Drug Metabolism & Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1517\/17425255.2015.986457","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T18:36:13Z","timestamp":1770402973000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1517\/17425255.2015.986457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,24]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1,2]]}},"alternative-id":["10.1517\/17425255.2015.986457"],"URL":"https:\/\/doi.org\/10.1517\/17425255.2015.986457","relation":{},"ISSN":["1742-5255","1744-7607"],"issn-type":[{"value":"1742-5255","type":"print"},{"value":"1744-7607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,24]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2014-11-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}